Financial StabilityThe company’s current cash runway is to the end of May 2025 and is actively exploring other financing solutions to extend its cash runway.
Funding NeedsAdditional financing required as the company’s current cash runway is to the end of May 2025.
Product Development RisksRisks include failure of TAH in clinical trials, failure to secure regulatory approval, and failure to achieve commercial success due to market size, penetration rate, and competition.